AUBURN, Alabama, Nov. 6 -- Auburn University posted the following news: * * * Auburn wins NCPA Chapter of the Year * For the fourth time in the last eight years, the Harrison College of Pharmacy's student chapter of the National Community Pharmacists Association (NCPA) was named National Chapter of the Year. The chapter was formally recognized during the NCPA Annual Convention in Kansas City in October. "It means so much more than just receiving an award, it means that community pharmacy was advocated for," said Laney Skipper Furey, last y more PR

HARTFORD, Connecticut, Nov. 7 -- The Connecticut Department of Consumer Protection issued the following news release: * * * DCP Food Sampling of Ground Cinnamon Initiates Multistate Recall Due to Elevated Lead Levels Lead testing in Connecticut resulted in a voluntary recall in 14 states 11/05/2026 HARTFORD -- The Department of Consumer Protection Food and Standards Team collected samples of Wise Wife Brand Ground Cinnamon, resulting in a multistate recall due to elevated lead levels that may be unsafe to consume. The samples were sent to more PR

NEW BRUNSWICK, New Jersey, Nov. 7 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release: * * * Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjogren's disease that reveal insights on importance of symptom improvements most valued by patients * New Brunswick, NJ. (November 7, 2026) - Johnson & Johnson (NYSE: JNJ) today announced new patient experience findingsa from the Phase 2 DAHLIAS study of nipocalimab in Sjogren's disease (SjD), a chronic, systemic autoantibody-driven disease affecti more PR

RARITAN, New Jersey, Nov. 7 [Category: BizPharmaceuticals] -- Johnson and Johnson Innovative Medicine posted the following news release: * * * Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjogren's disease that reveal insights on importance of symptom improvements most valued by patients * New Brunswick, NJ. (November 7, 2026) - Johnson & Johnson (NYSE: JNJ) today announced new patient experience findingsa from the Phase 2 DAHLIAS study of nipocalimab in Sjogren's disease (SjD), a chronic, systemic autoantibody-driven d more PR